This study is for people with advanced breast cancer that is hormone receptor positive (HR+) and HER2-negative (HER2-). You would have already received one CDK4/6 inhibitor (a type of targeted therapy) and your cancer has progressed. The goal is to see if an artificial intelligence (AI) model can help doctors choose the best second CDK4/6 inhibitor for you, combined with fulvestrant (Faslodex). Some participants will receive a different CDK4/6 inhibitor plus fulvestrant, while others will receive treatment chosen by their doctor (excluding CDK4/6 inhibitors). The main question is whether the AI-guided treatment can keep the cancer from getting worse for a longer time, measured at 6 months.

Study design

This is an open-label, randomized study involving about 105 participants. It compares two treatment approaches to see which is more effective.

What's involved

You will need to provide a tumor biopsy for genetic testing. You must also be willing to follow all study procedures and be available for the study's duration.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome of how long it takes for the cancer to get worse will be measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.